- Home
- FURY vs COYA Comparison
FURY vs COYA Comparison
Compare FURY & COYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- FURY
- COYA
- Stock Information
- Founded
- FURY 2008
- COYA 2020
- Country
- FURY Canada
- COYA United States
- Employees
- FURY N/A
- COYA N/A
- Industry
- FURY Precious Metals
- COYA Biotechnology: Pharmaceutical Preparations
- Sector
- FURY Basic Materials
- COYA Health Care
- Exchange
- FURY Nasdaq
- COYA Nasdaq
- Market Cap
- FURY 94.8M
- COYA 107.0M
- IPO Year
- FURY N/A
- COYA 2022
- Fundamental
- Price
- FURY $0.53
- COYA $6.15
- Analyst Decision
- FURY Strong Buy
- COYA Strong Buy
- Analyst Count
- FURY 1
- COYA 4
- Target Price
- FURY $1.40
- COYA $16.50
- AVG Volume (30 Days)
- FURY 198.8K
- COYA 59.2K
- Earning Date
- FURY 08-26-2025
- COYA 08-12-2025
- Dividend Yield
- FURY N/A
- COYA N/A
- EPS Growth
- FURY N/A
- COYA N/A
- EPS
- FURY N/A
- COYA N/A
- Revenue
- FURY N/A
- COYA $423,452.00
- Revenue This Year
- FURY N/A
- COYA $40.52
- Revenue Next Year
- FURY N/A
- COYA N/A
- P/E Ratio
- FURY N/A
- COYA N/A
- Revenue Growth
- FURY N/A
- COYA N/A
- 52 Week Low
- FURY $0.35
- COYA $4.65
- 52 Week High
- FURY $0.59
- COYA $10.24
- Technical
- Relative Strength Index (RSI)
- FURY 56.02
- COYA 51.12
- Support Level
- FURY $0.47
- COYA $5.60
- Resistance Level
- FURY $0.54
- COYA $6.28
- Average True Range (ATR)
- FURY 0.02
- COYA 0.41
- MACD
- FURY -0.00
- COYA -0.04
- Stochastic Oscillator
- FURY 74.44
- COYA 49.11
About FURY Fury Gold Mines Limited
Fury Gold Mines Ltd is a Canadian-focused exploration and development company strategically positioned in three prolific mining regions: James Bay, Quebec; the Golden Triangle, British Columbia; and the Kitikmeot Region Nunavut. Its projects include Eau Claire, Homestake Ridge, Committee Bay, Eleonore South JV, and Gibson MacQuoid.
About COYA Coya Therapeutics Inc.
Coya Therapeutics Inc is a clinical-stage biotechnology company focused on developing proprietary medicinal products to modulate the function of regulatory T cells. It is developing its multi-modality Treg therapies for neurodegenerative, autoimmune, and metabolic diseases.